Ground Lease AgreementGround Lease Agreement • March 11th, 2016 • Sucampo Pharmaceuticals, Inc. • Pharmaceutical preparations
UENO FINE CHEMICALS INDUSTRY LTD. (hereinafter, “Party A”), and R-Tech Ueno, Ltd. (hereinafter, “Party B”) form the following agreement regarding the ground lease of the land owned by Party A which is described at the end of the document (hereinafter, “This Land”).
AMENDMENT 1 TO THE LICENSE, DEVELOPMENT, COMMERCIALIZATION AND SUPPLY AGREEMENT FOR LUBIPROSTONESupply Agreement • March 11th, 2016 • Sucampo Pharmaceuticals, Inc. • Pharmaceutical preparations
This Amendment 1 is entered into as of 18 November 2015 (the “Effective Date”) by and between Sucampo AG, a corporation organized under the laws of Switzerland with principal offices at Baarerstrasse 22, CH-6300, Zug, Switzerland (“Sucampo”) and Takeda Pharmaceuticals International AG (formerly registered as Takeda Pharmaceuticals International GmbH), a corporation organized under the laws of Switzerland with principal offices at Thurgauerstrasse 130, 8152 Glattpark-Opfikon, Zurich, Switzerland (“Takeda”). Each of Takeda and Sucampo is referred to individually herein as a “Party” and collectively as the “Parties”.
Sucampo Pharmaceuticals, Inc. Duration-Based Stock Option Incentive Award Stock Option Agreement Terms and ConditionsStock Option Agreement Terms and Conditions • March 11th, 2016 • Sucampo Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
This Incentive Stock Option Agreement, along with the Sucampo Pharmaceuticals, Inc. Duration -Based Stock Option Incentive Award Summary delivered herewith (the "Award Summary"), once signed by the individual named on the Award Summary (the "Participant"), shall constitute an Agreement made as of the Grant Date (as indicated on the Award Summary), by and between Sucampo Pharmaceuticals, Inc., a Delaware corporation having its principal office at 805 King Farm Boulevard, Suite 550, Rockville, MD 20850 (“Sucampo” and with its direct and indirect subsidiaries, the "Company"), and the Participant.
Basic Transaction Agreement Concerning Outsourced Manufacturing R-Tech Ueno, Ltd. Nissan Chemical Industries, Ltd. Confidential and Proprietary CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE...Sucampo Pharmaceuticals, Inc. • March 11th, 2016 • Pharmaceutical preparations • Hyogo
R-Tech Ueno, Ltd. (hereinafter “R-Tech”) and Nissan Chemical Industries, Ltd. (hereinafter “Nissan Chemical”) hereby enter into the following agreement to signify that they have agreed as follows in regard to the outsourced manufacturing and supply of […***…], which is the synthetic raw material of RU-0211 developed as a new pharmaceutical by R-Tech.
CREDIT AGREEMENTCredit Agreement • March 11th, 2016 • Sucampo Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This Credit Agreement (as may be amended, restated, amended and restated, supplemented or otherwise modified from time to time, this “Agreement”) is entered into as of October 16, 2015, among Sucampo Pharmaceuticals, Inc., a Delaware corporation, each financial institution from time to time party hereto (collectively, the “Lenders” and individually, a “Lender”), and Jefferies Finance LLC, as Administrative Agent and Collateral Agent.
